However, our data indicate that absence of a functioning VDR does not blunt the pro-hypertrophic actions of FGF23 in vivo, and does not interfere with the TAC-induced increase in circulating Fgf23 or with the TAC-induced cardiac hypertrophy. This evidence concerns the gene VDR and cardiac hypertrophy.